Pearl River Capital’s Sage Therapeutics SAGE Stock Holding History

Pearl River Capital’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-103	Closed	-$10K	–	716
2018 Q4	$10K	Buy	+103	New	+$11.8K	0.05%	564

Other funds holding SAGE

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Pearl River Capital's SAGE Position: Q1 2019 in Review

Pearl River Capital sold out of Sage Therapeutics (SAGE) in Q1 2019, closing a stake of 103 shares — an estimated $10K sold.

Pearl River Capital first reported a position in SAGE in Q4 2018 and held it in 1 quarter. The position peaked at $10K in Q4 2018. 267 funds tracked by Wall St. Rank hold SAGE as of Q1 2019.

Pearl River Capital reported no remaining Sage Therapeutics position as of Q1 2019 after selling out during the quarter.
Pearl River Capital sold 103 Sage Therapeutics shares in Q1 2019, an estimated $10K.
Pearl River Capital first reported a position in Sage Therapeutics in Q4 2018 and held it in 1 quarter.
Pearl River Capital's Sage Therapeutics position peaked at $10K in Q4 2018.
267 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2019.

Based on Pearl River Capital's 13F filing for Q1 2019, filed 2 May 2019.